Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC28-0126 in STEMI Patients Undergoing PCI
NCT02770664Phase 2Unknown
- Sponsor
- LG Chem
- Start
- Apr 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LC28-0126 in ST-segment elevation myocardial infarction (STEMI) (4 arms), sponsored by LG Chem. Primary endpoint: Area Under the Curve of Troponin I at 72 hours. Status: unknown.
02
Drugs
LC28-0126
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02770664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770664.